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Background: The term “obesity paradox”, refers to lower mortality rates in obese patients,
and is evident in various chronic cardiovascular disorders. There is however, only scarce data
regarding the clinical implication of obesity and pulmonary hypertension (PH). Therefore, in
the current study, we evaluated the possible prognostic implications of obesity in PH patients.
Methods: We assessed 105 consecutive PH patients for clinical and hemodynamic parameters,
focusing on the possible association between Body Mass Index (BMI) and mortality. Follow-up
period was 19  13 months.
Results: Sixty-one patients (58%) had pre-capillary PH and 39 patients (37%) out-of-proportion
post-capillary PH. During follow-up period, 30 patients (29%) died. Death was associated with
reduced functional-class, inverse-relation with BMI, higher pulmonary artery and right atrial
pressures, pulmonary vascular resistance and signs of right ventricular failure. In multivariate
analysis, obesity (BMI  30 kg/m2), was the variable most significantly correlated with
improved survival [H.R 0.2, 95% C.I 0.1e0.6; p Z 0.004], even after adjustment for baseline
characteristics. Obese and very-obese (BMI  35 kg/m2) patients had significantly less
mortality rates during follow-up (12% and 8%, respectively) than non-obese patients (41%),
p Z 0.01. The tendency of survival benefit for the obese vs. non-obese patients wasension; BMI, body mass index; PAH, pulmonary arterial hypertension; PCWP, pulmonary capillary
ular resistance; TPG, trans-pulmonary gradient; RAP, right atrial pressure; PAP, pulmonary arterial
ation.
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140 B. Zafrir et al.maintained both in the pre-capillary (10% vs. 46% mortality, p Z 0.008) and disproportional
post-capillary PH patients (11% vs. 40% mortality, p Z 0.04).
Conclusions: Obesity was significantly associated with lower mortality in both pre-capillary
and disproportional post-capillary PH patients. It seems that in PH, similarly to other chronic
clinical cardiovascular disease states, there may be a protective effect of obesity, compatible
with the “obesity paradox”.
ª 2012 Elsevier Ltd. All rights reserved.Introduction
Pulmonary hypertension (PH) is defined as mean pulmonary
artery pressure (PAP) 25 mmHg at rest as assessed by right
heart catheterization. The clinical classification of PH
comprises heterogeneous conditions with different clinical
presentations, pathophysiology and management.1,2
Untreated, it is commonly associated with reduced prog-
nosis, leading to right ventricular failure.3e5
Hemodynamic classification of PH includes both pre-
capillary PH, typically in pulmonary arterial hypertension
(PAH) patients, and post-capillary PH which is evident in
patients with left heart dysfunction, and is probably the
most common etiology for elevated PAP. Most of the post-
capillary PH patients will have a passive increase in PAP due
to the backward transmission of the elevated left atrial
pressure. However, a subset of patients will have an
increase of mean PAP with increased trans-pulmonary
gradient (TPG; defined as mean PAP-PCWP 12 mmHg)
and pulmonary vascular resistance (PVR). As opposed to the
“passive” form, lowering the pulmonary capillary wedge
pressure (PCWP) to normal may not normalize the PAP.
These patients can develop severe PH which is also defined
as “reactive” or “out-of-proportion” post-capillary PH.6e9
Over the last several decades numerous studies identi-
fied specific prognostic variables associated with prognosis
in PH, especially in patients with PAH. Most of these
parameters were either hemodynamic or clinically
based.10e13 Parameters such as functional class and exer-
cise capacity measures, right atrial pressure (RAP), PVR,
cardiac index, presence of pericardial effusion, and labo-
ratory markers including brain natriuretic peptides and
troponin levels were reported with varying results.14e16
Body Mass Index (BMI), is an indicator of relative weight
for height (kg/m2) and a frequently used surrogate for
assessment of excess body fat. Although measuring total
body mass does not measure fat distribution directly, BMI is
adopted by the World Health Organization (WHO) as
a valuable measure of obesity.17
The relationship between BMI and total mortality risk is
controversial. Obesity is a well-recognized independent
cardiovascular risk factor. In the general population, a higher
BMI is associated with an increased risk for cardiovascular
events and death, and obesity has reached epidemic
proportions in developed countries.18 On the other hand, BMI
was shown tobe inversely associatedwith long termmortality
in several chronic diseases, including coronary artery
diseases, peripheral vascular disease, chronic obstructive
pulmonary disease and hemodialysis patients.17,19e23 This
phenomenon was even more prominent in heart failurepatients, a disease with high mortality in both reduced and
preserved systolic function.24e29
This unexpected manifestation of reverse epidemiology,
known as the “obesity paradox”, promoted several sug-
gested hypotheses trying to clarify the obesity paradox.19,30
However, the relationship between high BMI and mortality
remains a topic of considerable controversy.31e36
Data regarding the possible prognostic values of BMI in
PH is scarce. Recently, an NHLBI workshop in PH estab-
lishing priorities for specific clinical research needed to
advance care of patients with PH, recommended to
examine the role of obesity with pulmonary vascular
disease and RV dysfunction.37 Considering the lack of data
and referring to PH as a chronic progressive disorder with
heart failure manifestations, the aim of our study was to
evaluate the impact of BMI on mortality, focusing on two
groups of patients with PH, the pre-capillary PH patients as
opposed to patients with post-capillary PH.
Methods
Study population and data collection
Study population included 105 consecutive PH patients,
who underwent echocardiographic and hemodynamic
evaluation, at our PH referral tertiary medical center. PH
was defined as mean PAP of more than 25 mmHg, measured
by right heart catheterization. Study was approved by
Carmel Medical Center institutional review board (CMC 09-
0095; approval number 021-8109). Data collected for each
patient included: age, gender, weight, height and BMI (kg/
m2), WHO functional class (IeIV), signs of clinical right
heart failure, and laboratory values of blood creatinine and
hemoglobin levels. Obesity was defined as BMI of 30 kg/m2
or higher, according to the WHO definitions. BMI values
were calculated during the right heart catheterization. Co-
morbidities and risk factors were recorded according to
patients’ diagnoses, and included: smoking, hypertension,
diabetes mellitus, coronary artery disease, heart failure,
and renal dysfunction. Comprehensive two-dimensional
echocardiographic studies were performed in all patients.
Hemodynamic measurements
Diagnostic right heart catheterization was performed in all
patients, at rest, using Swan-Gantz catheter, according to
standard protocols.38 Baseline hemodynamic variables were
calculated at end-expiration, and included systemic arte-
rial pressure, mean RAP, PAP e (systolic, diastolic, mean),
Obesity paradox and pulmonary hypertension 141PCWP, blood oxygen saturations (mixed venous, pulmonary
artery and systemic artery), and measures of PVR and TPG.
Cardiac output and indexes were measured both by the
Fick’s and Thermodilution method.
PH was further classified by the hemodynamic defini-
tions of PH according to the European Society of Cardiology
(ESC) PH guidelines.1 Pre-capillary PH which was specified
as mean PCWP 15 mmHg, while post-capillary PH as PCWP
>15 mmHg, and was further classified into 2 types,
depending on the Trans-Pulmonary Gradient (TPG Z mean
PAP-PCWP); Reactive (out-of-proportion) post-capillary PH
with TPG >12 mmHg, and passive post-capillary PH with
normal TPG 12 mmHg. All the patients with pre-capillary
and out-of-proportion post-capillary PH had in addition an
elevated PVR of >3 Wood units.Data analysis
Continuous data are presented as means  standard devi-
ation (SD), and categorical variables as numbers or
percentages. The Independent-Samples T-test was used to
compare continuous variables, and the Chi-square tests
were used to compare categorical variables. Fisher’s exact
test was used in cases of small sample sizes. We analyzed
the clinical, echocardiographic and hemodynamic charac-
teristics of our PH patients and examined the relation of all
variables measured, with subsequent mortality during
follow-up period. Survival curves were plotted by the
KaplaneMeier method using the Log-rank test for compar-
ison between variables. Multivariate analysis was per-
formed by the Cox proportional e hazards regression
analysis. Hazard ratios for death were calculated, with 95%
confidence intervals (CI) between brackets. To determine if
the significant variables that differ between the obese and
non-obese patients remained significant, adjustment was
made for other risk factors and baseline characteristics
such as age, gender, smoking, diabetes mellitus and heart
failure measures. Survival analysis according to BMI values
of obesity, was further carried out in the two discrete
groups of patients with pre-capillary (n Z 61) and out-of-
proportion post-capillary (n Z 39) PH.Table 1 Baseline characteristics and co-morbidities in patients
Variable All patients (n Z 105)
Age (years) 66  12
Gender (F) 61 (58%)
World health organization
functional class (1e4)
2.9  0.7
Smoking 16 (15%)
Diabetes 39 (37%)
Hypertension 69 (65%)
Coronary artery disease 35 (33%)
Pericardial effusion 11 (11%)
Right heart failure 56 (53%)
BMI (kg/m2)a 28.7  5.0
Creatinine (mg/dl) 1.18  0.5
Hemoglobin (g/dl) 12.5  2.3
a BMI Z body mass index.The results were considered statistically significant
when the p-value was <0.05. The SPSS statistical software
was used to perform all statistical analyses.
Results
A total of 105 PH patients were included in the study. Mean
age of the study population was 66  12 years. Fifty-eight
percent of the patients were female. Patients’ character-
istics and major co-morbidities are presented in Table 1.
Half of the study cohort had evidence of clinical right heart
failure and the mean WHO functional class was 2.9  0.7.
Echocardiography and right heart catheterization were
accomplished in all study population, displaying PH hemo-
dynamics (Table 2). Sixty patients (57%) had an enlarged
right ventricular size, and 27 (26%) a reduced right
ventricular function, as assessed by 2-dimensional echo-
cardiography. The majority of the patients had preserved
left ventricular ejection fraction, with only 7% systolic
heart failure (LVEF < 45%). In addition, mean cardiac
output indices were in the low-normal range.
Mean follow up period was 19  13 months (median 17
months), during which 30 (29%) of the patients had died.
We performed univariate analysis to identify several factors
out of the patients characteristics that were associated
with increased mortality risk during follow up. Mortality
was associated with reduced WHO functional class
(3.4  0.7 vs. 2.8  0.7, pZ 0.001), a trend toward higher
incidence of pericardial effusion (20% vs. 7%, pZ 0.06) and
an inverse association with BMI values (26  4 vs. 30  5,
p Z 0.003), demonstrating lower mortality rates in higher
BMI patients (Table 1). Major co-morbid conditions such as
hypertension and diabetes mellitus had no significant
association.
Hemodynamic parameters of echocardiogram and right
heart catheterization, demonstrated several parameters in
correlation with mortality during follow-up. Smaller left
ventricular dimensions, higher PAP and RAP, echocardio-
graphic findings of right ventricle enlargement and systolic
dysfunction, lower systolic blood pressure, and elevated
PVR and TPG measurements, were all associated withwith PH, according to survival during follow-up.
Alive (n Z 75) Dead (n Z 30) p Value
65.6  11.8 68.9  10.8 0.18
41 (55%) 20 (66%) 0.28
2.8  0.7 3.4  0.7 0.001
11 (16%) 5 (16%) 1.00
27 (37%) 12 (41%) 0.66
49 (65%) 20 (67%) 0.64
27 (36%) 8 (27%) 0.26
5 (7%) 6 (20%) 0.06
37 (51%) 19 (63%) 0.28
30  5 26  4 0.003
1.15  0.4 1.24  0.5 0.37
12.8  2.3 11.8  2.2 0.09
Table 2 Echocardiographic and hemodynamic variables in patients with PH, according to survival during follow-up.
Variablea All patients (n Z 105) Alive (n Z 75) Dead (n Z 30) p-Value
LVEF (%) 57  9 52  10 59  3 0.1
LVEDD (cm) 4.5  0.8 4.6  0.8 4.1  0.6 0.007
LVESD (cm) 3.0  0.8 3.2  0.9 2.7  0.5 0.006
Left atrial dimension (cm) 4.2  0.8 4.2  0.7 4.1  0.9 0.54
Estimated systolic PAP (mmHg) 69  19 66  18 78  18 0.003
RAP (mmHg) 9.9  4.8 9  4 12  5 0.02
Moderateesevere T.R 54 (51%) 33 (46%) 21 (70%) 0.04
Enlarged RV size 60 (57%) 36 (49%) 24 (80%) 0.008
Reduced RV function 27 (26%) 13 (18%) 14 (47%) 0.006
Systolic blood pressure (mmHg) 133  21 134  23 123  17 0.03
RAP (mmHg) 11  6 10  5 13  7 0.09
Systolic PAP (mmHg) 69  21 66  20 77  20 0.01
PCWP (mmHg) 15  7
10  3
16  7 15  7 0.15
Trans-pulmonary gradient (mmHg) 26  13 24  12 31  12 0.018
PA saturation (%) 60  10 60  10 58  12 0.39
C.Oa e fick (l/min) 4.4  1.1 4.6  1.1 4.3  1.0 0.11
C.O e thermodilution (l/min) 4.5  1.2 4.6  1.1 4.3  1.2 0.29
C.Ia e fick (l/min/m2) 2.5  0.6 2.4  0.5 2.4  0.5 0.66
C.I e thermodilution (l/min/m2) 2.4  0.6 2.4  0.6 0.77
SVR (wood) 20  6 20  6 21  6 0.50
PVR (wood) 7.3  4 6  3 8  5 0.004
a LVEFZ Left Ventricular Ejection Fraction; LVEDDZ Left Ventricular End Diastolic Dimension; LVESDZ Left Ventricular End Systolic
Dimension; TRZ Tricuspid Regurgitation; PAZ pulmonary Artery; COZ Cardiac Output; CIZ Cardiac Index; SVRZ Systemic Vascular
Resistance; PVR Z Pulmonary Vascular Resistance.
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elevated left heart filling pressures had no significant
association with mortality.
In a multi-variable stepwise Cox regression analysis, out
of all the univariate correlated variables, only BMI and WHO
functional class measures were independently associated
with mortality (Table 3). Obesity (BMI  30 kg/m2) was the
best marker for survival prediction [H.R 0.2, 95% C.I
0.1e0.6; pZ 0.004], and was not affected by adjusting for
baseline characteristics or heart failure measures.
Dividing the study population to defined BMI groups
according to the WHO definitions, displayed that the obese
(BMI  30 kg/m2) and very-obese (BMI  35 kg/m2) patients
had significantly lower mortality rates during follow-up
(12% and 8%, respectively) than the non-obese patients
(41% mortality; p Z 0.01). Accordingly, the KaplaneMeierTable 3 Adjusted multivariate analysis of variables asso-
ciated with all-cause mortality during follow-up.
Variablea x2 p-Value Adjusted
hazard ratio
95% C.I
BMI 8.9 0.004 0.2 0.1e0.6
WHO functional class 6.7 0.01 1.9 1.2e3.4
a The following variables were entered the multi-variable Cox
model: Functional class, pericardial effusion, BMI, moder-
ateesevere T.R, right ventricular dysfunction, Systolic blood
pressure, PAP, PVR, RAP, Hemoglobin level. Risk adjustment was
made for age, gender, baseline risk factors and heart failure
measures.survival curves demonstrates significantly better survival
rates for the obese vs. the non-obese patients (Log rank
test, p < 0.001; Fig. 1).
The distribution of the BMI values in the study cohort
displayed a bell-shaped, normal appearance (Fig. 2).
Correlating the obese (41% of patients; BMI  30 kg/m2) and
non-obese patients (59% of patients; BMI < 30 kg/m2) for
baseline characteristics, there were no significant differ-
ences, except for a trend toward lower age in the obese
patients (64  12 vs. 67  11 years, p Z 0.06; Table 4).Figure 1 KaplaneMeiersurvivalcurves,forobese(BMI 30kg/m2)
and non-obese (BMI < 30 kg/m2) patients.
Figure 2 Distribution of BMI values in the study cohort.
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duration of the obese and non-obese patients (21  15 vs.
17  11 months, p Z 0.13).
In the current study we classified our patients based on
hemodynamic classification.
This classification is noted in several documents and
guidelines ofmajor Europeanandnon-European Societies and
is the basis for treatments options evaluation and serve as the
platform for the clinical sub-classification for PH working
groups .In pre-capillary PH the left heart filling pressure is
15 mmHg and pulmonary resistance is usually increased to
>3 Wood units. In post-capillary PH the left heart filling
pressure is increased to values >15 mmHg. Pre-capillary PH
includes the clinical groups 1, 3, 4, and 5,while post-capillary
PH is represented by the clinical group 2 [1, 6, 7, 14].
Performing a sub-group classification of the study pop-
ulation according to the hemodynamic definitions of PH, we
were able to divide most of our patients into two major
groups: the pre-capillary PH group with 61 (58%) of the
patients, and post-capillary group with 39 (37%) patients
which were all reactive, out-of-proportion PH patients. The
sub-group analysis demonstrates that the same tendency of
survival benefit for the obese patients is maintained in the
two discrete groups of patients, the pre-capillary and theTable 4 Characteristics and co-morbidities of obese vs.
non-obese patients.
Variable Non-obese
(59% of
patients)
Obese
(41% of
patients)
p-Value
Age (years) 67  11 64  12 0.06
Sex (F) 34 (56%) 26 (62%) 0.55
Smoking 10 (17%) 6 (14%) 0.65
Diabetes 21 (34%) 18 (44%) 0.27
Hypertension 40 (65%) 29 (66%) 0.68
Coronary artery disease 19 (31%) 16 (38%) 0.40
Right heart failure 30 (49%) 26 (61%) 0.23
LVEF (%) 57  9 56  10 0.63
Systolic PAP (mmHg) 71  20 66  22 0.23
Cardiac output (l/min) 4.42  1.1 4.56  1.1 0.53disproportional post-capillary patients. Mortality during
follow-up was observed in 10% and 11% of the obese
patients in these two groups, in comparison to 40% and 46%
mortality in the non-obese patients (p Z 0.008 and
p Z 0.04, respectively; Fig. 3).Discussion
The main finding of this study is that obesity is associated
with lower mortality in PH patients suggesting the exis-
tence of the “obesity paradox” in these patients, irre-
spectively of their left heart filling pressures. Specifically,
we demonstrated the importance of BMI evaluation in PH
patients as BMI 30 kg/m2 was strongly correlated with
improved survival, independent to other well-known prog-
nostic parameters including echocardiographic, hemody-
namic, functional assessment or demographic parameters.
In fact, comparing with all of these parameters, BMI was
found to be the strongest prognostic marker for mortality.
The survival advantage of the obese PH patients was
maintained in both patients with pre-capillary and dispro-
portional post-capillary PH, suggesting that higher BMI
serve as a protective marker in PH patients irrespectively of
their left heart filling pressures.
There are conflicting data regarding the correlation
between obesity and PH. Of note, even the possible asso-
ciation between obesity and elevated pulmonary pressures
is controversial.39,40 Recently, an analysis of the wide-scale
REVEAL registry in PAH patients, demonstrated that mean
BMI values are similar to a normal comparison group.41
However, in other studies, pulmonary venous hyperten-
sion was found to be associated with metabolic syndrome,
with higher BMI values in comparison with PAH patients.42
Yet, the vast majority of these studies had traditionally
concentrated on the relationship between obesity and PH
rather on the possible association between obesity and
mortality in PH patients.
Interestingly, Benza et al. demonstrated that a higher
BMI values with elevation of 10 kg/m2, were associated with
better survival in patients with pulmonary arterial hyper-
tension, supporting the notion of obesity protective role in
this sub-population of PH patients.43
Nevertheless, to the best of our knowledge, this current
study is the first to focus on the BMI as a prognostic
parameter in predicting mortality in PH patients; both pre
and post-capillary PH, representing a “real world” cohort of
patients, demonstrating the “obesity paradox” presents
irrespectively of the left heat filling measurements.
Data emerged in a variety of chronic cardiovascular
diseases, suggested that patients with higher BMI have better
survival rates comparing with normal and under-weight
patients.17,19 This replicated data of inverse relationship
between obesity and all-cause mortality, challenged clinical
reasoning and generated the concept of the “obesity
paradox”.31 The growing evidence supporting the protective
effect of obesity in chronic diseases is particularly recognized
in heart failure patients, inwhich the observations supporting
obesity paradox are accumulating in recent years.24e28,30
Higher catabolic burden, cardiac cachexia, and abnormal
cytokine and neurohormonal secretion, were all signaled to
play a role in the linkage between low BMI and high
Figure 3 Correlation of obesity with mortality during follow-up, according to subgroup analysis: pre-capillary and out-of-
proportion post-capillary PH patients.
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in heart failure pathogenesis and disease progression includ-
ing oxidative stress and systemic inflammation,44,45 it was
suggested that patients with higher BMI also have ametabolic
reserve, and with increased adipose tissue they may have
reduced systemic inflammation.25,30
Of note, albeit the vast data, the “obesity paradox” is still
far from being a consensus. It was suggested that bias
selection may play a role as obese patients often present
earlier in their disease course and thus treated more
appropriately than other patients. Interestingly, a trend of
lower age in the obese patients group was observed in our
study population as well. The lower BNP values seen in the
obese patients may also be a potential explanation for their
better prognosis in heart failure. Other critics of the “obesity
paradox” refer to small sample sizes of patients with short
follow-up periods and a U-shaped BMI-survival curve rela-
tionship was also pointed out.32,33 In addition, it is important
to note that BMI and obesity are not identical terms. BMI
parameter is not a good surrogate for body fat in certain
populations as the elderly. Accordingly, other parameters
may be more accurate in quantifying and defining obesity
such as adiposity distribution, the degree of visceral and
ectopic fat burden, and percent body fat.46,47 It is also
conceivable that BMI clinical implications are different in
health and disease states, and thus the observation of
inverse relation between BMI and mortality in populations of
chronic diseases may not be generalized to healthy pop-
ulations.31 Albeit BMI may not be the ideal parameter to
reflect obesity, it has significant advantages as being easily
calculated parameter with proven overall risk prediction
capabilities in a wide variety of medical disorders.35
Our study has several limitations. As stated above, BMI
represents total body mass and other adiposity markers
may better define obesity. The number of patients in each
PH subtype category was not large and therefore might
have influenced on the survival analyses of obese vs. non-
obese patients in those subgroups.
As noted throughout this article, in the current study we
categorized PH patients based on a hemodynamic classifi-
cation. Therefore, the pre-capillary PH group might have
different demographic characteristics than cohorts of WHO
group 1 PH patients, such as the REVEAL registry, in whichthe mean age of subjects was younger, with less co-
morbidities, and even a higher percentage of women.48
The prevalence of obesity in our patients’ cohort (41%)
was high. However, it is not significantly higher than in the
REVEAL registry, in which the percentage of obesity was
33%, and even 38% in the idiopathic PAH group, suggesting
that the high rate of obesity does not reflect a selection
bias of a less severe PH cohort.
Larger prospective and longitudinal studies are needed in
order to better evaluate the association between BMI values,
obesity, and mortality in various subgroups of PH patients.
In conclusion, in a cohort of PH patients, higher BMI
values were significantly associated with lower mortality
risk, independent to other prognostic variables, both in pre-
capillary and out-of-proportion post-capillary PH patients.
Similar to several other chronic cardiovascular diseases,
including heart failure, the “obesity paradox” seems to
exist in PH patients as well.Acknowledgments
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